Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

Table 2

Demographic and clinical characteristics of the patients.

Characteristics	aaPRP treatment
Characteristics
Age, yr	52.1 ± 8.89
Male sex, %	40
Female sex, %	60
No. of coexisting conditions, no./total no. (%)
Two	4/10 (40)
Three	4/10 (40)
Four	2/10 (20)
Coexisting conditions, no./total no. (%)
Type 2 diabetes	4/27 (14.81)
Hypertension	2/27 (7.41)
Congestive heart failure (CHF)	3/27 (11.11)
Disseminated intravascular coagulation (DIC)	7/27 (25.93)
Community-acquired pneumonia (CAP)	4/27 (14.81)
Coronary artery disease (CAD)	1/27 (3.70)
Chronic kidney disease (CKD)	1/27 (3.70)
Lung pulmonary tuberculosis	1/27 (3.70)
Atrial fibrillation	1/27 (3.70)
Hypo-Na	1/27 (3.70)
Metabolic encephalopathy	1/27 (3.70)
Happy hypoxia	1/27 (3.70)